Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PF 07261271

Drug Profile

PF 07261271

Alternative Names: PF-07261271

Latest Information Update: 25 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Class Anti-inflammatories; Bispecific antibodies
  • Mechanism of Action Interleukin 12 subunit p40 inhibitors; Interleukin 23 inhibitors; Tumour necrosis factor ligand superfamily member 15 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammatory bowel diseases

Most Recent Events

  • 29 Feb 2024 Pfizer completes a phase I trial in Inflammatory bowel diseases (In volunteers) in USA (SC, IV) (NCT05536440)
  • 31 Oct 2023 Telavant has an exclusive option to collaborate with Pfizer on global development of the p40/TL1A directed bispecific antibody PF-07261271 before October 2023 (Telavant pipeline, October 2023)
  • 17 Oct 2022 Phase-I clinical trials in Inflammatory bowel diseases (In volunteers) in USA (IV) (NCT05536440)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top